Vaxcyte (PCVX) Operating Leases (2021 - 2026)

Vaxcyte (PCVX) has 6 years of Operating Leases data on file, last reported at $116.3 million in Q1 2026.

• On a quarterly basis, Operating Leases rose 43.43% year-over-year to $116.3 million in Q1 2026; TTM through Mar 2026 was $116.3 million, a 43.43% increase from a year earlier, with the FY2025 full-year figure at $111.5 million, up 70.9% from the prior year.
• Operating Leases for Q1 2026 stood at $116.3 million, up from $111.5 million in the prior quarter.
• Over the last five years, Operating Leases for PCVX reached as high as $116.3 million in Q1 2026 and fell as low as $7.8 million in Q3 2023.
• Historically, Operating Leases has averaged $41.3 million across 5 years, with a median of $18.3 million in 2024.
• Across the five-year window, Operating Leases surged 6371.11% in 2022 and slumped 41.74% in 2023, its largest moves.
• Year by year, Operating Leases stood at $12.9 million in 2022, then surged by 71.4% to $22.1 million in 2023, then soared by 194.96% to $65.2 million in 2024, then soared by 70.9% to $111.5 million in 2025, then gained by 4.34% to $116.3 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $116.3 million in Q1 2026, $111.5 million in Q4 2025, and $78.7 million in Q3 2025.